Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis
The FASEB Journal · 15.06.2024 · 38 (11)
DOI: 10.1096/fj.202301773r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 07.06.2024. Verfasst von Yihua Bai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Mesenchymal Stem Cells, Smad2 Protein, Smad3 Protein. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Joint Funds For Applied Basic Research of Yunnan Science and Techology Department-Kunming Medical University, MOST | National Natural Science Foundation of China (NSFC), Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders in Yunnan Province.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is one of the common microvascular complications in diabetic patients. Marrow mesenchymal stem cells (MSCs) have attracted attention in DN therapy but the underlying mechanism remains unclear. Here, we show that MSC administration alleviates high glucose (HG)‐induced human kidney tubular epithelial cell (HK‐2 cell) injury and ameliorates renal injury in DN mice. We identify that Smad2/3 is responsible for MSCs‐regulated DN progression. The activity of Smad2/3 was predominantly upregulated in HG‐induced HK‐2 cell and DN mice and suppressed with MSC administration. Activation of Smad2/3 via transforming growth factor‐β1 (TGF‐β1) administration abrogates the protective effect of MSCs on HG‐induced HK‐2 cell injury and renal injury of DN mice. Smad2/3 has been reported to interact with methyltransferase of N6‐methyladenosine (m6A) complex and we found a methyltransferase, Wilms' tumor 1‐associating protein (WTAP), is involved in MSCs‐Smad2/3‐regulated DN development. Moreover, WTAP overexpression abrogates the improvement of MSCs on HG‐induced HK‐2 cell injury and renal injury of DN mice. Subsequently, α‐enolase (ENO1) is the downstream target of WTAP‐mediated m6A modification and contributes to the MSCs‐mediated regulation. Collectively, these findings reveal a molecular mechanism in DN progression and indicate that Smad2/3/WTAP/ENO1 may present a target for MSCs‐mediated DN therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
ORCID-Profile: Yihua Bai, Lilan Huang, Yang Fan, Yaling Li
Förderung
- The Joint Funds For Applied Basic Research of Yunnan Science and Techology Department-Kunming Medical University
- MOST | National Natural Science Foundation of China (NSFC)
- Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders in Yunnan Province
- Yunnan Revitalization Talent Support Program [Youth talent project]
- National Natural Science Foundation of China
Zitieren
APA
Bai, Y., Huang, L., Fan, Y., & Li, Y. (2024). Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis. The FASEB Journal, 38(11). https://doi.org/10.1096/fj.202301773r
Vancouver
Bai Y, Huang L, Fan Y, Li Y. Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis. The FASEB Journal. 2024;38(11). doi:10.1096/fj.202301773r
BibTeX
@article{Bai2024,
author = {Bai, Yihua and Huang, Lilan and Fan, Yang and Li, Yaling},
title = {Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis},
journal = {The FASEB Journal},
year = {2024},
volume = {38},
number = {11},
doi = {10.1096/fj.202301773r}
}
EUVIMED